Environmental

CLRB provides no disclosed R&D intensity in the supplied metrics, limiting evidence of peer-leading environmental innovation or process efficiency versus more transparent biotech peers.

The absence of reported gross profit margin and free-cash-flow margin data constrains assessment of resource efficiency, leaving its environmental cost profile less visible than peers with fuller disclosure.

Low debt-to-equity and moderate net debt-to-EBITDA suggest limited balance-sheet pressure, which can reduce incentives for environmentally harmful short-term cost cutting versus more levered peers.

No Tier 1 filing evidence was provided for emissions, energy use, or waste management, so environmental positioning cannot be confirmed as stronger than peers on operational sustainability.

Social

No disclosed workforce, safety, or clinical-trial conduct metrics were provided, making CLRB’s social risk management less assessable than peers with more complete reporting.

Zero stock-based compensation to revenue in the supplied data suggests limited dilution pressure, but it does not by itself demonstrate stronger employee alignment than peers.

The lack of reported R&D spending intensity reduces visibility into patient-focused innovation commitments, which are material social factors for biotech companies relative to peers.

Without filing-based disclosure on diversity, labor practices, or community impact, CLRB appears broadly average on social transparency rather than clearly advantaged versus peers.

Governance

Very low debt-to-equity indicates a relatively conservative capital structure, which can support governance flexibility versus peers that rely more heavily on leverage.

Net debt-to-EBITDA remains moderate, suggesting manageable creditor oversight and less refinancing pressure than more indebted peers, but not a clear governance advantage.

Zero stock-based compensation to revenue points to restrained equity dilution, which is generally favorable for capital discipline versus peers with heavier compensation-driven issuance.

Governance assessment remains limited because no filing-based board, audit, or insider-ownership disclosures were provided, leaving CLRB’s oversight quality unverified relative to peers.

Overall Score

CLRB’s ESG positioning appears broadly average versus peers because limited disclosure and only modestly favorable capital-discipline signals outweigh the absence of material ESG evidence.

Score Driver: Insufficient Filing-Based ESG Disclosure Limits Confirmation Of Any Structural Peer Advantage.